Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25051610 | 0.84 | HSD17B10 (0.39) | SMN1; SMN2LMNAKDM4ECYP2C19TSHR | |
| SCHEMBL29020997 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAKDM4ECYP2C19TSHR | |
| SCHEMBL7442378 | 0.78 | ELANE (0.41) | SMN1; SMN2LMNATSHRNPSR1OPRM1 | |
| SCHEMBL5446397 | 0.77 | CYP19A1 (0.38) | SMN1; SMN2LMNAKDM4ECYP2C19TSHR | |
| SCHEMBL7435181 | 0.77 | KDM4E (0.40) | SMN1; SMN2LMNAKDM4ECYP2C19TSHR | |
| SCHEMBL11079770 | 0.77 | LMNA (0.61) | SMN1; SMN2LMNAKDM4ECYP2C19TSHR | |
| SCHEMBL1665837 | 0.76 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAKDM4ECYP2C19CYP19A1 | |
| SCHEMBL7436133 | 0.74 | — | — | |
| SCHEMBL14376977 | 0.72 | KDM4E (0.32) | SMN1; SMN2LMNAKDM4ECYP2C19TSHR | |
| SCHEMBL7438840 | 0.71 | TSHR (0.31) | TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
| US-7790739-B2 | receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one | Merck & Co., Inc. and Merck Sharp & Dohme Corp. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7625936-B2 | 3,5-Diphenyl-4,5-dihydro-1H-dipyrazole derivatives such as {2-[1-acetyl-3-(2,5-difluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-5-yl]ethyl}(dimethyl)silanol that are useful for treating cancer | MERCK & CO. INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| US-7618971-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090247565-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | disclosed |
| US-7579355-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1599446-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GABALACTAM | HIKAL LTD (IN) | 2009-08-12 | — | — | EP | disclosed |
| US-7550478-B2 | Tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070149536-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070142388-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070129309-A1 | Conjugates useful in the treatment of prostate cancer | BRADY STEPHEN F | 2007-06-07 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
| US-4079011-A | Composition containing a polyvinylpyrrolidone and method for stimulating well production | TEXACO INC. (US) | 1978-03-14 | — | — | US | disclosed |
| US-3962110-A | POLYVINYL PYRROLIDONE | TEXACO INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149536-A1 | Inhibitors of Akt activity | AKT1, AKT2, AKT3 | SMN1; SMN2 3892/4885LMNA 4297/4885KDM4E 1347/4885 |
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, RET | SMN1; SMN2 4077/4885LMNA 3170/4885KDM4E 791/4885 |
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | SMN1; SMN2 3055/4885LMNA 4548/4885KDM4E 849/4885 |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | SMN1; SMN2 3181/4885LMNA 3729/4885KDM4E 4205/4885 |
| US-20070129309-A1 | Conjugates useful in the treatment of prostate cancer | BPHL, KLK3, DNPEP | SMN1; SMN2 3213/4885LMNA 3715/4885KDM4E 1171/4885 |
| US-20070142388-A1 | Inhibitors of Akt activity | AKT2, AKT1, AKT3 | SMN1; SMN2 3497/4885LMNA 4480/4885KDM4E 1493/4885 |
| US-20090247565-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | SMN1; SMN2 3373/4885LMNA 4646/4885KDM4E 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.